Background: The advent of new antiretrovirals has expanded the therapeutic options for multiple drugresistant HIV-1 infection. The role of recycled nucleoside reverse transcriptase inhibitors (NRTIs) in this scenario remains uncertain.
Introduction
The advent of newer antiretrovirals against new targets and new-generation drugs within old classes, with a higher genetic barrier and a different resistance profile, has expanded the therapeutic options for patients with multiclass drug-resistant HIV-1 infection, who had limited options with previous drugs. The most recently licensed agents are the new protease inhibitor (PI) darunavir, the new non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine, the integrase inhibitor raltegravir and the CCR5 antagonist maraviroc. In randomized clinical trials, each of these new drugs has shown high efficacy as a component of salvage therapy in highly experienced patients, especially in subjects in whom two or preferably three fully active agents were added to the study drug. 1 -4 Combinations with three of these new drugs have only been evaluated in observational cohort studies but exceptional results have been reported, showing that complete and sustained virological suppression (,50 copies/mL) is now an achievable therapeutic goal even for subjects with multidrug-resistant HIV-1 infection. 5 -7 All trials with new agents in highly treatment-experienced patients have included optimized background regimens that contain nucleoside reverse transcriptase inhibitors (NRTIs), and so NRTIs are often included in advanced salvage regimens in daily clinical practice. Although some NRTIs can maintain activity against HIV even in the presence of resistance mutations, NRTIs with reduced antiviral activity may not be necessary if three new active drugs are available.
The aim of this study was to assess the contribution of NRTIs to the efficacy of salvage regimens containing three of the newest antiretrovirals in patients with multidrug-resistant HIV-1 infection, in a real clinical practice setting.
Methods
A prospective observational study of all consecutive HIV-1-infected adults who started a new salvage antiretroviral regimen that included at least three of the new drugs darunavir, etravirine, raltegravir and maraviroc was performed in six hospitals in Spain between April 2007 and April 2009.
Patients were eligible if they met the following inclusion criteria: (i) failure to a current antiretroviral regimen (defined as two consecutive determinations of viral load above 50 copies/mL); (ii) prior failure to NRTIs, NNRTIs and PIs; (iii) a genotypic resistance test performed while on treatment with the last failing regimen available and documented resistance to at least one drug of each class (NRTIs, NNRTIs and PIs), based on current or historical genotypic resistance tests.
The components of the new salvage therapy were selected by the clinicians attending each patient. The regimen had to include at least three of the new drugs (400 mg of raltegravir twice daily, 200 mg of etravirine twice daily, 150 mg of maraviroc twice daily if associated with a boosted PI and 300 mg or 600 mg twice daily otherwise and 600/100 mg of ritonavir-boosted darunavir twice daily) and physicians could also decide to add NRTIs or not. For the study, patients were divided into two groups: (i) NRTI-sparing regimens; and (ii) NRTIcontaining regimens.
In those patients who received maraviroc, virus tropism for CCR5 co-receptor had been confirmed by Trofile w phenotypic assay (Monogram Biosciences, South San Francisco, CA, USA).
The study protocol was approved by the institutional review boards of the coordinator centre and informed consent was obtained from all patients.
As phenotypic or virtual phenotypic resistance testing was not available in all centres, the activity of each antiretroviral drug in the salvage regimen was assessed according to the cumulative resistance profile, based on all available genotypic resistance tests for each patient. Drug resistance-associated mutations (RAMs) were considered as defined by the International AIDS Society-USA guidelines. Susceptibility to darunavir and etravirine were also predicted by using currently available response-based weighted scores. The number of active drugs in each regimen was calculated according to the Stanford HIV Resistance Database (HIVdb version 6.0.5) interpretation algorithm and 1, 0.5 or 0 point was assigned to each drug in the regimen if low-level or no resistance, intermediate resistance or high resistance, respectively, was present. Drugs of the new classes (raltegravir and maraviroc), were considered to be fully active if they had not been used previously. NRTIs were considered partially active in cases of intermediate resistance and inactive in cases of high resistance.
Periodical evaluations of the patients, including physical examination and laboratory tests, were performed at baseline and at weeks 4, 12, 24, 36 and 48.
The primary endpoint was the percentage of patients with plasma viral load (HIV-1 RNA) below 50 copies/mL at week 48 in each treatment group. Secondary endpoints were the number of clinical and laboratory adverse advents and the number of adverse events leading to drug discontinuation.
SPSS software for Windows (Version 15.0; SPSS, Chicago, IL, USA) was used for statistical analyses. Categorical variables were compared by the x 2 test or Fisher's exact test and continuous variables by the nonparametric Mann-Whitney U-test.
Other variables that could have influenced the efficacy endpoint [number of previous drugs, highly active antiretroviral therapies (HAARTs), virological failures and resistance mutations to NRTIs, NNRTIs and PIs, CD4 cell count at baseline, HIV plasma viral load at baseline and number of active drugs in the regimen] were analysed by univariate and multivariate logistic regression models.
All statistical tests were two-tailed and performed at a level of statistical significance of 0.05.
Results
One hundred and twenty-two patients were included in the study, comprising 59 in the NRTI-sparing group and 63 in the NRTI-containing group. Patients' baseline characteristics are shown in Table 1 . All patients had a long history of HIV and treatments. The median plasma viral load at baseline was 3.9 log 10 HIV-1 RNA copies/mL and 38% of patients had a CD4 cell count below 200 cells/mm 3 . The most used regimens were the combinations raltegravir/etravirine/ritonavir-boosted darunavir in 75 cases (61%) and raltegravir/maraviroc/ritonavir-boosted darunavir in 33 cases (27%). Among patients who received NRTIs, tenofovir/emtricitabine (65%) and lamivudine alone (16%) were the most used drugs. Almost 90% of these patients received lamivudine or emtricitabine. NRTIs were considered to be partially active in 43/63 patients and inactive in 20/63 patients. Without taking into account the NRTIs used, 65% of the patients received three fully active drugs, and all patients received at least two fully active new drugs in the regimen.
Overall, 95/122 patients (78%) achieved plasma HIV-1 RNA suppression below 50 copies/mL at week 48. Differences between the NRTI-sparing and NRTI-containing groups were not significant in either the intent-to-treat analysis (ITT; loss of follow-up and missed HIV-1 RNA values were considered as failures) or the on-treatment analysis (lost patients without previous virological failure were censored). After 48 weeks of treatment, 46/59 patients (78%, 95% CI 67%-88%) in the NRTI-sparing group and 49/63 patients (78%, 95% CI 67%-88%) in the NRTI-containing group achieved HIV-1 RNA suppression below 50 copies/mL in the ITT analysis (P¼1). In the on-treatment analysis, these percentages increased to 85% (95% CI 76%-95%) in the NRTI-sparing group and 82% (95% CI 72%-91%) in the NRTI-containing group (P¼0.81) (Figure 1 ).
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There were no significant differences in the percentages of patients achieving HIV-1 RNA below 50 copies/mL at week 48. When the NRTI-sparing group was compared with the subgroups of patients who received partially active NRTIs (46/59, 78% versus 34/43, 80%, P¼ 0.62) or inactive NRTIs (46/59, 78% versus 13/20, 65%, P ¼ 0.28).
Similar results were observed when the analysis was focused only on patients with fewer than three new active drugs, although the number of patients was low (21 patients in the NRTI-sparing group and 22 patients in the NRTI-containing group).
The variables significantly associated with a worse virological response were a CD4 cell count less than 200 cells/mm 3 at baseline [odds ratio (OR) 0.41, 95% CI 0.17-0.97] and a higher plasma HIV viral load at baseline (OR 0.68, 95% CI 0.48-0.96, per 1 log increase), but only in the univariate analysis.
After 48 weeks, the CD4 cell count increased by a median of 87 cells/mm 3 [interquartile range (IQR) 29-181] in the NRTIcontaining group and 116 cells/mm 3 (IQR 21 -259) in the NRTI-sparing group (P ¼0.91).
The incidence of adverse events related to therapy was 5/63 (8%) in the NRTI-containing group and 1/59 (2%) in the NRTI-sparing group (P ¼ 0.2). Rash related to etravirine occurred in three patients, all in the NRTI-containing group, leading to discontinuation in one patient. One patient in the NRTI-sparing group presented a rash attributed to darunavir not leading to drug discontinuation. One patient in the NRTI-containing group Imaz et al.
discontinued darunavir because of grade 2 diarrhoea. Three subjects required NRTI withdrawal: tenofovir because of grade 2 renal failure; stavudine because of lipoatrophy; and didanosine because of the high risk of mitochondrial toxicity in combination with ribavirin. Three patients died during the study period, one in the NRTI-containing group and two in the NRTI-sparing group. No death was related to antiretroviral (ARV) drugs (one AIDS-related death and two non-AIDS-related deaths occurred).
Discussion
The results of our study confirm the high efficacy of the current salvage regimens composed of three of the new ARV drugs in patients with multidrug-resistant HIV-1 infection. Furthermore, the rate of HIV RNA suppression was similar in patients receiving and not receiving NRTIs in their regimen.
There is some evidence that NRTIs could potentially retain residual antiviral activity despite full or partial HIV resistance through indirect effects related to impaired viral fitness of some NRTI-resistant mutants. The maintenance of lamivudine in the presence of resistance, as confirmed by M184I/V mutation, has been associated with at least some degree of viral suppression but this additional activity has been evident only in non-suppressive regimens. 8 Recycled didanosine, stavudine and tenofovir have shown efficacy in some patients with prior failures to NRTIs. However their utility is limited by toxicity concerns and poor response when there is a large number of RAMs. 9 Other possible benefits of NRTIs could be the antagonistic interactions between some NRTI RAMs. 10 In our study, all patients were naive to integrase inhibitors and to CCR5 antagonists. Despite all patients being heavily treatment-experienced, there was no significant resistance to etravirine and darunavir according to genotypic tests (Table 1) . Thus, all patients received at least two and 65% received three fully active drugs regardless of the inclusion of NRTIs in the regimen.
The high percentage of patients with three fully active new drugs and the efficacy shown by these combinations made it difficult to find additional benefits attributable to residual activity of NRTIs.
The rate of adverse events was only slightly higher in the NRTI-containing group. However, the NRTI had to be stopped in three subjects, which supports the idea that inactive NRTIs should be avoided in salvage regimens in order to reduce the risk of toxicity. Of note, this strategy cannot be applied in patients with chronic hepatitis B virus (HBV) infection in whom the maintenance of NRTIs with activity against HBV is necessary.
The main limitations of this study are those related to the non-randomized design. Patients in the NRTI-containing group had received a higher number of prior ARV drugs and HAART regimens. Although this could be interpreted as selection bias (a more severe salvage situation could have influenced the decision to give an NRTI), the number of prior drugs or regimens was not related to the treatment response. Furthermore, the number of previous failures, the resistance profile, the percentage of patients with CD4 cell count less than 200 cells/mm 3 and the HIV plasma viral load at baseline were similar in both groups. Thus, we do not expect that this baseline difference had any significant impact on the efficacy differences between the two treatment arms.
Another limitation is the reduced number of patients with fewer than three active drugs in the regimen, which made it difficult to evaluate the residual effect of inactive NRTIs in this subgroup of patients.
In conclusion, salvage regimens with three active drugs chosen from the new agents raltegravir, maraviroc, etravirine and darunavir are highly effective in patients with extensive drug-resistant HIV-1 infection. Our results suggest that partially active or inactive NRTIs may be unnecessary in this scenario. Furthermore, inactive or partially active NRTI-sparing salvage regimens could reduce treatment toxicity, complexity and costs, and this strategy should be evaluated in prospective randomized trials, such as the ongoing ACTG 5241 study (http://clinicaltrials. gov, identifier NCT00537394). NRTI-sparing salvage regimens for multidrug-resistant HIV 361 JAC
